Acute Bacterial Skin And Skin Structure Infections Market Growth Trajectory Through 2024-2033

Spread the love

The Acute Bacterial Skin And Skin Structure Infections Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Acute Bacterial Skin And Skin Structure Infections Market:

https://www.thebusinessresearchcompany.com/report/acute-bacterial-skin-and-skin-structure-infections-global-market-report

According to The Business Research Company’s Acute Bacterial Skin And Skin Structure Infections Global Market Report 2024, The acute bacterial skin and skin structure infections market size has grown rapidly in recent years. It will grow from $10.57 billion in 2023 to $11.75 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to healthcare industry innovation, economic factors, patient population trends, evolving diagnostic methods, clinical trial innovation..

The acute bacterial skin and skin structure infections market size is expected to see strong growth in the next few years. It will grow to $17.17 billion in 2028 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to global epidemiological factors, market entry of new therapies, rapid diagnostic tools, patient-centric approach, shifting treatment guidelines.. Major trends in the forecast period include patient population demographics, antibiotic resistance concerns, advancements in treatment strategies, prevalence of methicillin-resistant staphylococcus aureus (mrsa), focus on outpatient treatment..

The rising prevalence of skin infections is expected to propel the growth of the acute bacterial skin and skin structure infections market going forward. Skin infections are conditions in which microorganisms, such as bacteria, fungi, or viruses, invade and multiply within the skin, leading to various symptoms and discomfort. The rise in skin infections creates a greater demand for therapeutic solutions, antibiotics, and innovative treatments to address acute bacterial and skin structure infections, ensuring patients can access the best possible care and outcomes. For instance, in September 2022, according to the UK Health Security Agency (UKHSA), a UK-based national executive agency, the %age of Methicillin-resistant Staphylococcus aureus (MRSA) cases caused by skin and soft tissue infections increased to 33.7% in 2022 from 2021. Moreover, MRSA cases increased by 25.7% in the financial year from April 2020 to March 2021. Therefore, the rising prevalence of skin infections will drive the growth of the acute bacterial skin and skin structure infections market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=13282&type=smp

The acute bacterial skin and skin structure infections market covered in this report is segmented –

1) By Type Of Infection: Hospital-acquired Acute Bacterial Skin And Skin Structure Infections, Community-acquired Acute Bacterial Skin And Skin Structure Infections

2) By Active Ingredients: Delafloxacin, Vancomycin, Ceftaroline fosamil, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, Other Active Ingredients

3) By Route of Administration: Oral, Parenteral, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By Application: Cellulitis, Abscess, Surgical Wounds, Traumatic Wound

Major companies operating in the acute bacterial skin and skin structure infections market are focused on developing innovative single-dose therapies, such as Dalbonova, to gain a competitive edge in the market. Dalbonova is a single-dose therapy that provides convenience and effectiveness so patients can achieve their desired results with just one potent 1500 mg dose administered once. For instance, in August 2023, BDR Pharmaceuticals Internationals Pvt. Ltd., an India-based pharmaceutical company that focuses on API (active pharmaceutical ingredient) and formulation therapeutic segments, including acute bacterial skin and skin structure infections, launched Dalbonova injection, a single-dose therapy for acute bacterial skin and skin structure infections (ABSSSI). Dalbonova Injection reduces the risk of hospital-acquired diseases By offering single-dose treatment and eliminating the need for hospital admissions. It is designed to treat acute bacterial skin and skin structure infections (ABSSSI) caused by certain gram-positive microorganisms in patients of all ages, including newborns.

The acute bacterial skin and skin structure infections market report table of contents includes:

Executive Summary
Acute Bacterial Skin And Skin Structure Infections Market Characteristics
Acute Bacterial Skin And Skin Structure Infections Market Trends And Strategies
Acute Bacterial Skin And Skin Structure Infections Market – Macro Economic Scenario
Global Acute Bacterial Skin And Skin Structure Infections Market Size and Growth

Global Acute Bacterial Skin And Skin Structure Infections Market Competitive Benchmarking
Global Acute Bacterial Skin And Skin Structure Infections Market Competitive Dashboard
Key Mergers And Acquisitions In The Acute Bacterial Skin And Skin Structure Infections Market
Acute Bacterial Skin And Skin Structure Infections Market Future Outlook and Potential Analysis
Appendix

Top Major Players: